Ph.D., Senior Vice President for Research and Development, HTG Molecular Diagnostics

Dr. Roche joins HTG from Ventana Medical Systems/Roche Tissue Diagnostics where he served as Vice President of Translational Diagnostics and was responsible for interfacing with pharmaceutical partners in their development of targeted cancer therapeutics and facilitating the transition of biomarkers into companion diagnostics. Dr. Roche also led reagent product development at Ventana, launching over thirty in vitro diagnostic (IVD) products, including the FDA-approved c-kit and HER2 tests. Prior to his time at Ventana, Dr. Roche served as Director of the Immunohistochemistry Laboratory and Associate Professor of Pathology and Biochemistry-Molecular Biology for Mayo Clinic Rochester. Dr. Roche has co-authored more than 125 peer-reviewed publications.


Session: Genetics-Informed Personalized Immunotherapy

As the oncology community stares down the cresting wave of promising new immunotherapies, it is clear that new biomarker strategies are needed to choose among the myriad available checkpoint modulators for a given patient-- BITEs, CAR-Ts, oncolytic viruses, and neoantigens. This session features speakers who are developing genetics-informed personalized immunotherapy approaches and will highlight the current state, the roadmap for the future, and what challenges remain in matching the patient with the optimal therapeutic combination. In addition, Dr. Roche will provide an overview of the opportunity to more fully assess the immune host response using targeted next-generation sequencing.

Web Analytics